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METHODS: Data were extracted from Medstat’s 
MarketScan, a proprietary claims database, which
includes people who received pharmacy and medical 
beneﬁts from various managed care organizations. We
identiﬁed patients with continuous pharmacy coverage
and at least one pharmacy claim in 1999. The AD group
consisted of all those with at least one ICD-9 code for 
AD (691.8 or 692.9), and the control group consisted of
a 1 :1 match on age of those without AD. Antihistamine
use was deﬁned as at least one prescription during 1999.
The risk ratio and risk difference were calculated to
compare those with AD to the control group. Differences
in drug costs are estimated using the average AWP.
RESULTS: 40,998 people were identiﬁed with AD and at
least one pharmacy claim in 1999. 38.8% of AD patients
used antihistamines—13.6% had a prescription for a ﬁrst
generation product and 29.5% had a prescription for a
second generation product. Among the control group,
only 7.7% received an antihistamine prescription; 1.7%
for a 1st generation and 6.3% had a prescription for a
second generation product. The risk ratio for the more
costly 2nd generation products was 4.67 (95% CI: 4.48,
4.86), and for the 1st generation products, 7.83 (95% CI:
7.25, 8.45). The risk difference was 23.2% (95% CI:
22.7%, 23.7%) and 11.9% (95% CI: 11.5%, 12.2%),
respectively. The difference in per patient antihistamine
costs (AWP) was $40.47 for 2nd generation products and
$1.84 for 1st generation products.
CONCLUSIONS: Despite the lack of evidence support-
ing the use of antihistamines to treat patients with atopic
dermatitis, there is over a ﬁve-fold increase in use com-
pared to people without AD. This potentially inappro-
priate use translates to a substantial economic burden to
third party payers.
GASTROINTESTINAL DISEASES/DISORDERS—
Clinical Outcomes Presentations
PGI1
EFFECTIVENESS OF MEDICAL INTERVENTIONS
IN PATIENTS WITH SYMPTOMS OF GERD—A
SYSTEMATIC REVIEW
Edwards S1, Wahlqvist P2
1AstraZeneca UK Ltd, Hertfordshire, UK; 2AstraZeneca R&D
Mölndal, Mölndal, Sweden
OBJECTIVES: To extract outcome data on the probabil-
ity of symptom resolution for acute drug treatment and
symptomatic relapse for long-term drug treatment in
patients with gastro-esophageal reﬂux disease (GERD),
by drug, dose and by patient category (non-endoscoped
GERD, endoscopy-veriﬁed reﬂux esophagitis and GERD
without esophagitis). The results were intended for use in
cost-effectiveness evaluations, where data on esophagitis
healing or remission have traditionally been used as a 
deﬁnition of success in the treatment of GERD.
METHODS: A systematic literature search for ran-
domised controlled trials of medical interventions for
GERD was carried out in September 2000 by a contract
research organisation, the Evidence Research Unit, UK.
The citations uncovered underwent a series of ﬁltering
steps for applicability and methodological quality. Where
possible, extracted data were pooled.
RESULTS: Very few of the 82 identiﬁed studies were
found to contain relevant data as a basis for the sympto-
matic probabilities required. Reliable pooled data were
only found for complete resolution of heartburn after 
4 weeks’ acute treatment with omeprazole 20mg od 
in patients with esophagitis (60.9%, n = 1,233) and in
patients with GERD without esophagitis (63.5%, n =
525, p > 0.05 for the difference between groups). Only
one study was identiﬁed concerning the 6-month proba-
bility of symptomatic relapse during no drug treatment
(i.e., not placebo) in GERD patients with esophagitis
(90%, n = 145) and without esophagitis (75%, n = 123,
p < 0.001 for the difference between groups).
CONCLUSIONS: Reliable symptomatic probabilities
intended for cost-effectiveness evaluations of medical
interventions for GERD could not be sufﬁciently obtained
in this systematic review of randomised controlled trials.
PGI2
THERAPEUTIC COMPARABILITY OF 
PROTON PUMP INHIBITORS
von Scheele B, Sherrill B, Richter A, Devlin P
RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVE: This evidence-based review evaluates the
therapeutic comparability of ﬁve proton pump inhibitors
(PPIs): omeprazole, lansoprazole, pantoprazole, rabe-
prazole and esomeprazole for short-term treatment of
uncomplicated gastroesophageal reﬂux disease (GERD).
METHODS: A literature search identiﬁed 68 randomized
clinical trials comparing the PPIs to each other, to placebo
and/or to other anti-reﬂux treatments (histamine-2-
receptor [H2]-blockers). Evidence tables were compiled
for common outcomes and meta-analyses conducted. Efﬁ-
cacy was assessed on heartburn relief, esophageal healing,
overall GERD symptom relief, and withdrawals due to
lack of efﬁcacy. Safety was analyzed using withdrawals
due to adverse events, total adverse events, abdominal
pain, diarrhea, nausea and headache.
RESULTS: Meta-analyses found no differences between
the PPIs in heartburn relief, overall GERD symptom
relief, and withdrawals due to lack of efﬁcacy. The analy-
sis detected a statistically signiﬁcant efﬁcacy advantage 
of esomeprazole (20 and 40mg/day) over omeprazole 
(20mg/day) in acute erosive esophagitis healing rates.
Broad and speciﬁc safety outcomes were comparable
among the PPIs.
CONCLUSION: In the evidence collected here, the ﬁve
PPIs appear to be generally comparable for relief of
GERD symptoms. For treatment of acute erosive
esophagitis, both doses of esomeprazole were shown here
to be more beneﬁcial than omeprazole (20mg/day). In
terms of safety, the PPIs as a class have a remarkably low
incidence of side effects with few differences between
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them. Further evaluation is needed to determine the safety
of long-term use.
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PGI3
IMPACT OF PROTON PUMP INHIBITOR
UTILIZATION PATTERNS ON
GASTROESOPHAGEAL REFLUX 
DISEASE-RELATED COSTS
Hall JA1, Dodd SL2, Durkin M2, Sloan S2
1Ingenix Pharmaceutical Services, Eden Prairie, MN, USA;
2Janssen Pharmaceutica,Titusville, NJ, USA
OBJECTIVE: To determine proton pump inhibitor (PPI)
treatment patterns and their affect on gastroesophageal
reﬂux disease-related costs.
METHODS: This study used claims data to identify 
continuously enrolled GERD-diagnosed subjects newly
treated with a proton pump inhibitor (PPI) between
October 1, 1999 and March 31, 2000. Data were ana-
lyzed for six months following PPI initiation. Results were
stratiﬁed by ﬁrst PPI ﬁlled during the study period. Com-
pliance (measured by possession ratio), dosage escalation
(>25% of initial dose), and daily average consumption
(DACON) were measured. Subjects were assigned to one
of four GERD severity groups based on ICD-9 diagnosis
codes. Regression analysis was performed on GERD-
related costs using treatment patterns and type of PPI
drug as covariates of interest. Confounders including
GERD severity were controlled for in the analysis.
RESULTS: Of 75,452 subjects, there were 51,232
(67.9%) lansoprazole, 22,829 (30.3%) omeprazole and
1,391 (1.8%) rabeprazole subjects. Possession ratio was
not signiﬁcantly different by drug. Only 3.5% of rabepra-
zole subjects escalated versus 5.5% of omeprazole 
subjects and 9.3% of lansoprazole subjects (p = 0.0001).
Among subjects with esophageal ulcer or hiatal hernia,
rabeprazole users had a signiﬁcantly lower ﬁnal DACON
(1.03) versus both lansoprazole (1.20) and omeprazole
subjects (1.22, p = 0.0299). From the regression models,
subjects who were compliant with therapy (ratio ≥ 0.80)
had 43% higher GERD-related pharmacy costs and 33%
higher GERD-related total costs (both p < 0.001). GERD-
related medical costs were not signiﬁcantly affected by
compliance. Subjects who ﬁlled lansoprazole had 9.4%
higher GERD-related pharmacy costs versus rabeprazole
subjects (p < 0.01). Omeprazole subjects had 12.5%
higher GERD-related total costs versus rabeprazole sub-
jects (p < 0.01), while lansoprazole subjects had 18%
higher GERD-related total costs versus rabeprazole 
subjects (p < .001).
CONCLUSIONS: Rabeprazole subjects had lower
GERD-related costs, less escalation and lower DACON
compared to lansoprazole and omeprazole subjects. Com-
pliance was not signiﬁcantly different between drugs, nor
did it decrease GERD-related costs.
PGI4
PGI5
COST-EFFECTIVENESS OF IV PPI’S IN THE
TREATMENT OF NON-VARICEAL UPPER GI
BLEEDING FOLLOWING URGENT ENDOSCOPY
Herba K1, Barkun A1, Kennedy WA2, Fallone CA1,
RUGBE Investigators A1
1McGill University Health Centre, Montreal, QC, Canada;
2University of Montreal, Montreal, QC, Canada
OBJECTIVES: Recent clinical studies report lower 30-
day rebleeding rates associated with the use of intra-
venous proton pump inhibitors (IV PPIs) for treatment of
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